Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
Fiche publication
Date publication
septembre 2017
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R,
Lien Pubmed
Résumé
To evaluate the effectiveness and tolerance of mycophenolate mofetil (MMF) as a first-line treatment in neuromyelitis optica spectrum disorder (NMOSD).
Mots clés
Adolescent, Adult, Aged, Aquaporin 4, immunology, Autoantibodies, immunology, Autoantigens, immunology, Child, Cohort Studies, Female, Humans, Immunoglobulin G, Immunosuppressive Agents, therapeutic use, Male, Middle Aged, Mycophenolic Acid, therapeutic use, Myelin-Oligodendrocyte Glycoprotein, immunology, Neuromyelitis Optica, drug therapy, Recurrence, Young Adult
Référence
Mult. Scler.. 2017 Sep;23(10):1377-1384